Literature DB >> 11454603

Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors.

E Kodani1, K Shinmura, Y T Xuan, H Takano, J A Auchampach, X L Tang, R Bolli.   

Abstract

Recent studies have demonstrated that the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) and the adenosine A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) produce a delayed phase of protection against infarction similar to the late phase of ischemic preconditioning (PC). However, the mechanism for adenosine A1 or A3 receptor-induced late PC remains unknown. The goal of this study was to determine whether the delayed cardioprotective effects of adenosine A1 or A3 receptors are mediated by cyclooxygenase-2 (COX-2), which is an obligatory mediator of ischemic PC. We found that COX-2 protein expression (Western blotting) did not increase 24 h after the administration of either CCPA (100 microg/kg iv) or IB-MECA (300 microg/kg iv) compared with controls. To probe the role of constitutive COX-2 expression, conscious rabbits were subjected to 30-min coronary occlusion followed by 72-h reperfusion. Twenty-four hours before the occlusion, the rabbits were pretreated with CCPA (100 microg/kg iv) or IB-MECA (300 microg/kg iv). Both CCPA and IB-MECA resulted in a marked (approximately 47%) reduction in infarct size vs. controls [36.2 +/- 4.0% of the risk region (n = 9), 31.2 +/- 4.7% (n = 9), and 59.5 +/- 3.8% (n = 9), respectively; P < 0.05], similar to that induced by the late phase of ischemic PC [31.8 +/- 3.2% (n = 9)]. The selective COX-2 inhibitor N-(2-[cyclohexyloxy]4-nitrophenyl)methanesulfonamide (NS-398, 5 mg/kg), which abolished the protective effect of ischemic late PC, failed to block the protection of either CCPA or IB-MECA, indicating that COX-2 does not mediate the delayed protection of either CCPA or IB-MECA [CCPA + NS-398, 29.1 +/- 3.4% (n = 7); IB-MECA + NS-398, 34.9 +/- 2.9% (n = 8)]. NS-398 in itself did not affect infarct size [54.9 +/- 3.7% (n = 9)]. Taken together, these results demonstrate that, in contrast to ischemia-induced late PC, the mechanisms of adenosine A1 or A3 receptor-induced late PC is independent of COX-2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454603     DOI: 10.1152/ajpheart.2001.281.2.H959

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit.

Authors:  Giuseppe Rossoni; Marcelo N Muscara; Giuseppe Cirino; John L Wallace
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.

Authors:  John A Auchampach; Zhe-Dong Ge; Tina C Wan; Jeannine Moore; Garrett J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-04-10       Impact factor: 4.733

Review 3.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

4.  Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Yu-Ting Xuan; Yanqing Zhu; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-18       Impact factor: 4.733

5.  Cyclooxygenase-2 mediates the delayed cardioprotection induced by hydrogen sulfide preconditioning in isolated rat cardiomyocytes.

Authors:  Li-Fang Hu; Ting-Ting Pan; Kay Li Neo; Qian Chen Yong; Jin-Song Bian
Journal:  Pflugers Arch       Date:  2007-09-28       Impact factor: 3.657

6.  A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion.

Authors:  Idit Matot; Carolyn F Weiniger; Evelyne Zeira; Eithan Galun; Bhalchandra V Joshi; Kenneth A Jacobson
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.